MedTrace Logo

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

NCT00080327 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2013-11-11

No results posted yet for this study

Summary

A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia

Conditions

Interventions

DRUG

Aripiprazole

Tablets, Oral, 2mg, Once daily, 6 weeks.

DRUG

Aripiprazole

Tablets, Oral, 5mg, Once daily, 6 weeks.

DRUG

Aripiprazole

Tablets, Oral, 10mg, Once daily, 6 weeks.

DRUG

Placebo

Tablets, Oral, 0mg, Once daily, 6 weeks.

Sponsors & Collaborators

  • Otsuka America Pharmaceutical

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2004-09-30
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00080327 on ClinicalTrials.gov